Literature DB >> 15302734

Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.

Grzegorz Opolski1, Adam Torbicki, Dariusz A Kosior, Marcin Szulc, Beata Wozakowska-Kaplon, Piotr Kolodziej, Piotr Achremczyk.   

Abstract

STUDY
OBJECTIVES: The relative risks and benefits of strategies of rate control vs rhythm control in patients with atrial fibrillation (AF) remain to be fully explored.
DESIGN: The How to Treat Chronic Atrial Fibrillation (HOT CAFE) Polish trial was designed to evaluate in a randomized, multicenter, and prospective manner the feasibility and long-term outcomes of rate control vs rhythm control strategies in patients with persistent AF. PATIENTS: Our study population comprised 205 patients (134 men and 71 women; mean [+/- SD] age, 60.8 +/- 11.2 years) with a mean AF duration of 273.7 +/- 112.4 days. The mean observation period was 1.7 +/- 0.4 years. One hundred one patients were randomly assigned to the rate control group and received rate-slowing therapy guided by repeated 24-h Holter monitoring. Direct current cardioversion and atrioventricular junctional ablation with pacemaker placement were alternative nonpharmacologic strategies for patients with tachycardia that was resistant to medical therapy. One hundred four patients were randomized to sinus rhythm restoration and maintenance using serial cardioversion supported by a predefined stepwise antiarrhythmic drug regimen (ie, disopyramide, propafenone, sotalol, and amiodarone). In both groups, thromboembolic prophylaxis followed current guidelines. MEASUREMENTS AND
RESULTS: At the end of follow-up, 63.5% of patients in the rhythm control arm remained in sinus rhythm. No significant differences in the composite end point (ie, all-cause mortality, number of thromboembolic events, or major bleeding) were found between the rate control group and the rhythm control group (odds ratio, 1.98; 95% confidence interval, 0.28 to 22.3; p > 0.71). The incidence of hospital admissions was much lower in the rate control arm (12% vs 74%, respectively; p < 0.001). New York Heart Association functional class improved in both study groups, while mean exercise tolerance, as measured by the maximal treadmill workload, improved only in the rhythm control group (5.2 +/- 5.1 vs 7.6 +/- 3.3 metabolic equivalents, respectively; p < 0.001). The rhythm control strategy led to an increased mean left ventricular fractional shortening (29 +/- 7% vs 31 +/- 7%, respectively; p < 0.01). One episode of pulmonary embolism occurred in the rate control group despite oral anticoagulation therapy, while three patients in the rhythm control arm of the study experienced ischemic strokes (not significant).
CONCLUSIONS: The Polish HOT CAFE study revealed no significant differences in major end points between the rate control group and the rhythm control group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302734     DOI: 10.1378/chest.126.2.476

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  94 in total

Review 1.  Atrial fibrillation (chronic).

Authors:  Deirdre A Lane; Stavros Apostolakis; Christopher J Boos; Gregory Y H Lip
Journal:  BMJ Clin Evid       Date:  2011-11-10

Review 2.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 3.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 4.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

Review 5.  Can ablation prevent the excess mortality of atrial fibrillation?

Authors:  Elad Anter; David J Callans
Journal:  Curr Cardiol Rep       Date:  2010-09       Impact factor: 2.931

Review 6.  Atrial fibrillation: established and innovative methods of evaluation and treatment.

Authors:  Hans-Joachim Trappe
Journal:  Dtsch Arztebl Int       Date:  2012-01-09       Impact factor: 5.594

Review 7.  Rate control in the medical management of atrial fibrillation.

Authors:  A J Camm; I Savelieva; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

8.  [Rate and rhythm control in atrial fibrillation : pharmacological approaches].

Authors:  K F Weipert; D Erkapic; J Schmitt
Journal:  Herz       Date:  2015-02       Impact factor: 1.443

Review 9.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 10.  Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.

Authors:  Harry J G M Crijns
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.